Navigation Links
VivaScope(R) Confocal Imager May Eliminate Need for Routine Skin Biopsies for Dermatology Patients
Date:10/16/2007

ROCHESTER, N.Y., Oct. 16 /PRNewswire/ -- Many routine surgical biopsies could become a thing of the past as dermatologists may soon be sharing, reviewing and diagnosing noninvasive digital images of skin cells via the Internet, using Lucid Inc.'s VivaNet(TM) telemedicine server and its VivaScope(R) confocal imagers.

The technology, which relies on using special microscopes to digitally image a patient's skin, may bypass the need to surgically biopsy many patients. "VivaScope imaging sessions require only 5 to 10 minutes of a physician's assistant's time," said Jay Eastman, Ph.D., CEO, Lucid Inc. (http://www.lucid-tech.com).

The cellular resolution images may then be used by physicians to assist in forming a clinical judgment for a variety of skin conditions, including, for example, melanoma, basal cell carcinoma, actinic keratoses, and contact dermatitis.

A typical VivaScope imaging session produces two types of images of the patient's skin: dermatoscopic-quality, full-color macroscopic pictures, and microscopic, cellular resolution images. Like a routine biopsy, the images can then be read by a dermatologist or a pathologist and the diagnosis presented to the patient.

"Just as MRI and CT scans have largely eliminated the need for routine exploratory surgery, in-vivo confocal imaging may one day eliminate the need for routine invasive skin biopsy," Eastman stated.

Improving Quality of Life for Dermatology Patients

Already, dozens of Lucid's VivaScopes are in regular use throughout the U.S. and Europe. "Lucid's VivaScope(R) 1500 has the capability of imaging virtually all types of skin cancers, which makes it useful for many everyday procedures in a dermatology practice," stated Dr. Harold Rabinovitz, a Florida based dermatologist who specializes in skin cancer. "The VivaScope is an incredible diagnostic tool and now routinely aids me in the clinical evaluation of potential skin cancers."

The Company is also developing an Internet-based application, the Lucid VivaNet(TM), to enable the transfer of VivaScope digital images between practitioners and pathologists for rapid review of confocal images. The VivaNet technology conforms to DICOM (Digital Imaging and Communications in Medicine), an internationally accepted standard for the secure storage, retrieval and transfer of medical images, and it complies with federal HIPAA requirements for privacy and integrity of medical data.

Ultimately, the VivaNet could make VivaScope images available for review by other dermatologists and pathologists -- anywhere in the world -- in minutes, not days -- thus enabling rapid, real-time professional collaboration. The ultimate goal is that practitioners will rapidly receive a pathologic interpretation of confocal images from a VivaScope session, potentially assisting the practitioner in arriving at a clinical judgment while the patient is still in the doctor's office, Eastman said.

"It's our hope that the VivaScope and VivaNet will improve the quality of life for dermatology patients by eliminating the need for painful, invasive skin biopsies and drastically reducing the time required for diagnosis and treatment," Eastman said.

For information on Lucid's VivaScope or VivaNet technology, contact Lucid by phone at 585-239-9800, by email at info@lucid-tech.com, or on the web at http://www.lucid-tech.com. Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Jay Eastman, Ph.D. http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=62055


'/>"/>
SOURCE Lucid Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Satellite Imagery to monitor the Social Impact Of Geographical Changes
2. Three Teslas magnetic resonance imager acquired. Shot in the arm for research
3. Jumping genes eliminate sections of DNA
4. a New Pill Can eliminate menstruation
5. Bush Urged To Press India To Eliminate Medical Tariffs
6. Elephantiasis Is Eliminated In Egypt Due To Mass Drug Administration
7. Campaign to Eliminate Cervical Cancer
8. Inculcating Positive Thoughts Could Eliminate Depressive Mood
9. Researchers claim That Regular Use Of Hib Vaccine In Africa Could Eliminate H. Influenza totally.
10. Hospitals To Get Extra Consultants To Eliminate A&E Crisis
11. HIV discrimination in workplace should be eliminated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... Twenty years ago it was revolutionary: enabling the people ... the voices they hear. But this approach has proven transformative, both for people who ... gained credibility and now is used around the world, but it still lags in ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... commercial molecular diagnostics device that enables unprecedented portability and convenience. , The Cube ... four inches cubed in size, the Cube fits easily into any space, whether ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... WaterField Designs, ... digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal ... canvas or ballistic nylon, the Duo is smartly designed for Dad’s grooming ...
(Date:5/31/2016)... ... May 31, 2016 , ... Phynd Technologies, Inc. announced recently the signing of ... TX and Shore Medical Center – Somers Point, NJ. The new clients range in ... demonstrating the breadth of Phynd’s solution and its interoperability. , Houston Methodist is a ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... firm and statement solutions provider, for the tenth consecutive year as a ... issue of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... Mich. , May 31, 2016  Diplomat Pharmacy, Inc. ... pharmacy, has announced that Phil Hagerman , Chairman & ... the upcoming William Blair 36 th Annual Growth Stock ... Mr. Hagerman and Mr. Whelan are scheduled to present at ... Central Time. A live audio-only webcast of the presentation and ...
(Date:5/31/2016)... , May 31, 2016 Mundipharma ... initiation of a first-in-human clinical trial of its investigational ... - S101 is currently being developed for the treatment ... is designed to evaluate the safety and tolerability of ... several sites across the United States ...
(Date:5/31/2016)... The global biomaterials market is driven by the ... from chronic diseases. According to research report, "Global Biomaterials Market ... Forecasts (2016-2021) - (By Value; By Material Type - Polymer, ... By Region-North America, Europe , APAC, ROW; ... Italy , Japan , ...
Breaking Medicine Technology: